TABLE 4.
Primary and secondary outcomes for patients receiving CI versus II oxacillin
| Outcome or parameter | No. (%) of patients or daysa
|
P value | OR (95% CI)b | ||
|---|---|---|---|---|---|
| CI or II (overall) | CI (n = 78) | II (n = 29) | |||
| 30-Day microbiological cure | 97 (91) | 73 (94) | 23 (79) | 0.03 | 3.8 (1.06-13.6) |
| Hospital LOSc | 21 | 20 | 25 | 0.4 | |
| 30-Day mortality | 9 (8) | 6 (8) | 3 (10) | 0.7 | 0.7 (0.2-3.1) |
| Clearance of bacteremia | 7 | 7 | 7 | 0.5 | |
| Time to defervescence | 3 | 3 | 3 | 0.8 | |
| Duration of therapy | 42 | 42 | 39 | 0.6 | |
| Concurrent administration of gentamicind | 63 (59) | 40 (51) | 23 (79) | 0.009 | 0.3 (0.1-0.8) |
a
Results represent the numbers of days (median values for clearance of bacteremia and time to defervescence), except results for 30-day microbiological cure, 30-day mortality, and concurrent administration of gentamicin, which represent the numbers (percentages) of patients.
b
OR, odds ratio; 95% CI, 95% confidence interval.
c
LOS, length of stay.
d
Gentamicin was administered at 1 mg/kg of body weight for every 8-h dosing period.